Wilms tumor
Revision as of 15:08, 16 December 2018 by Jwarner (talk | contribs) (→Dactinomycin & Vincristine {{#subobject:3f9a1a|Regimen=1}})
Section editor | |
---|---|
Wayne H. Liang, MD, MS Birmingham, AL Twitter: WayneLiangMD |
3 regimens on this page
3 variants on this page
|
All lines of therapy
Dactinomycin monotherapy
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Wolff et al. 1968 | Randomized (E) | Single course of dactinomycin | Seems to have superior RFS |
Preceding treatment
Chemotherapy
- Dactinomycin (Cosmegen) 15 mcg/kg IV once per day on days 1 to 5
6-week cycle for 3 cycles, then 3-month cycle for 4 cycles
References
- Wolff JA, Newton WA Jr, Krivit W, D'Angio GJ. Single versus multiple dose dactinomycin therapy of Wilms's tumor: a controlled co-operative study conducted by the Children's Cancer Study Group A (formerly Acute Leukemia Co-operative Chemotherapy Group A). N Engl J Med. 1968 Aug 8;279(6):290-4. link to original article PubMed
- Update: Wolff JA, D'Angio G, Hartmann J, Krivit W, Newton WA Jr. Long-term evaluation of single versus multiple courses of actinomycin D therapy of Wilms's tumor. N Engl J Med. 1974 Jan 10;290(2):84-6. link to original article contains verified protocol PubMed
Dactinomycin & Vincristine
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
de Kraker et al. 2004 (SIOP 93-01) | Phase III (E) | Prolonged chemotherapy | Equivalent EFS |
Pritchard-Jones et al. 2015 (SIOP WT 2001) | Phase III (E) | Dactinomycin, Doxorubicin, Vincristine | Non-inferior EFS |
Preceding treatment
Chemotherapy
References
- SIOP 93-01: de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade MF; SIOP. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet. 2004 Oct 2-8;364(9441):1229-35. link to original article PubMed
- SIOP WT 2001: Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015 Sep 19;386(9999):1156-64. Epub 2015 Jul 9. link to original article PubMed